🔗 Permalink

Inventor profile of:

John Scholler

City:

Narberth, Pennsylvania

Country:

United States

Published Applications:

Last publication date:

2026-05-21

Top Assignees for applications by John Scholler

The entities that hold a legal rights for patent applications filed by inventor Scholler John:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 21 PHILADELPHIA, PA United States
NOVARTIS AG 10 Basel, Switzerland
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 4 Pittsburgh, PA United States

Recent patent applications by Scholler John

John Scholler from Narberth, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-21

US20260139061A1

Chemistry; metallurgy

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

#2 | 2025-09-25

US20250295774A1

Human necessities

COMPOSITIONS AND METHODS FOR GENERATING A PERSISTING POPULATION OF T CELLS USEFUL FOR THE TREATMENT OF CANCER

#3 | 2025-07-03

US20250215096A1

Chemistry; metallurgy

CHIMERIC ANTIGEN RECEPTOR THERAPY IN COMBINATION WITH IL-15R AND IL15

#4 | 2024-09-12

US20240301024A1

Chemistry; metallurgy

USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE

#5 | 2024-07-18

US20240238396A1

Human necessities

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

#6 | 2023-08-03

US20230242612A1

Chemistry; metallurgy

USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS

#7 | 2022-02-24

US20220056116A1

Chemistry; metallurgy

Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer

#8 | 2021-12-02

US20210371495A1

Chemistry; metallurgy

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

#9 | 2021-09-16

US20210284752A1

Chemistry; metallurgy

TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

#10 | 2021-02-11

US20210038659A1

Human necessities

COMBINATION THERAPY USING A CHIMERIC ANTIGEN RECEPTOR

#11 | 2021-01-14

US20210009652A1

Chemistry; metallurgy

Use of ICOS-based cars to enhance antitumor activity and car persistence

#12 | 2020-12-24

US20200399383A1

Chemistry; metallurgy

CHIMERIC ANTIGEN RECEPTOR THERAPY IN COMBINATION WITH IL-15R AND IL15

#13 | 2019-11-21

US20190352369A1

Chemistry; metallurgy

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

#14 | 2019-10-31

US20190330356A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

#15 | 2019-05-09

US20190135940A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

#16 | 2019-03-21

US20190085063A1

Chemistry; metallurgy

Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

#17 | 2018-12-27

US20180371068A1

Chemistry; metallurgy

Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

#18 | 2018-02-08

US20180037625A1

Chemistry; metallurgy

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

#19 | 2017-12-21

US20170362295A1

Chemistry; metallurgy

Use of ICOS-based CARS to enhance antitumor activity and CAR persistence

#20 | 2017-07-27

US20170209492A1

Human necessities

SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS

#21 | 2017-06-29

US20170183415A1

Chemistry; metallurgy

Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

#22 | 2017-01-12

US20170008963A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

#23 | 2015-01-22

US20150024482A1

Chemistry; metallurgy

Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

#24 | 2015-01-15

US20150017141A1

Chemistry; metallurgy

Use of ICOS-based CARs to enhance antitumor activity and CAR persistence

#25 | 2014-12-18

US20140370045A1

Chemistry; metallurgy

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

#26 | 2014-10-30

US20140322275A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

#27 | 2014-10-30

US20140322212A1

Chemistry; metallurgy

Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells

#28 | 2014-09-18

US20140271635A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

InventorID:

952713 ⎘